Comparative study of efficacy of L-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode.


Abstract

INTRODUCTION: Role of L-5-hydroxytryptophan (L-5-HTP) in depression is relatively less studied but the literature has shown its robust role in depression. The present randomized double blind study was undertaken to assess the role of L-5-HTP as an antidepressant and to compare its antidepressant efficacy with fluoxetine in first depressive episode patients of Indian population.

METHODS: A total of 70 patients of first depressive episode, all of whom were diagnosed with ICD-10 criteria, were recruited but only 60 patients completed the study and were randomly divided into two groups, receiving L-5-HTP and fluoxetine, respectively, for a period of 8 weeks. All patients were administered Hamilton Rating Scale for Depression (HAM-D) to assess severity of depression at baseline, 2 weeks, 4 weeks and 8 weeks. The efficacy of treatment was assessed by comparing HAM-D scores obtained at these examinations with the baseline examination; final evaluation of both efficacy and tolerance was assessed using the Clinical Global Impression (CGI) scale at the end of study.

RESULTS: Both treatment groups showed significant and nearly equal reduction in HAM-D scores beginning at week two and continuing through week eight. Twenty-two patients (73.33%) in the L-5-HTP group and 24 patients (80%) in the fluoxetine group showed positive response at the end of the study.

CONCLUSION: L-5-HTP has definitely got antidepressant effect in patients of depression. Antidepressant effect was seen within 2 weeks of treatment and was apparent in all degrees of depression. The therapeutic efficacy of L-5-HTP was considered as equal to that of fluoxetine.

Copyright © 2012 Elsevier B.V. All rights reserved.

PMID: 23380314 DOI: 10.1016/j.ajp.2012.05.011 [Indexed for MEDLINE]